EGFR and pancreatic ductal adenocarcinoma: In pancreatic cancer, the epidermal growth factor receptor (EGFR) is expressed in 30–90% of patients with pancreatic ductal adenocarcinoma (PDAC)4–6, marking aggressive disease with poor survival rates.